Interferon Alfa-2b in Treating Patients With Melanoma and Early Lymph Node Metastasis
Completed · Phase 3
Conditions studied: Melanoma (Skin)
In brief
RATIONALE: Interferon alfa-2b may interfere with the growth of cancer cells. PURPOSE: Randomized phase III trial to study the effectiveness of interferon alfa-2b in treating patients who have melanoma with early lymph node metastasis.
Key facts
- Study ID
- NCT00004196
- Run by
- University of Alabama at Birmingham
- People needed
- 3000
- Starts
- 1999-10-01
- Expected to finish
- 2007-11-01
- Last updated by the study team
- 2014-01-20
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Alabama at Birmingham Comprehensive Cancer Center — Birmingham, Alabama, United States
- James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky, United States
- Cancer Institute of New Jersey — New Brunswick, New Jersey, United States
- Roswell Park Cancer Institute — Buffalo, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.